Proteomic characterization of head and neck cancer patient-derived xenografts

Molecular Cancer Research

Volumn 14, Issue 3, 2016, Pages 278-286

  Li, Hua ^a   Wheeler, Sarah ^a   Park, Yongseok ^b   Ju, Zhenlin ^c   Thomas, Sufi M ^d   Fichera, Michele ^a   Egloff, Ann M ^a   Lui, Vivian W ^e   Duvvuri, Umamaheswar ^a,f   Bauman, Julie E ^a   Mills, Gordon B ^c   Grandis, Jennifer R ^a,g  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLUSTER ANALYSIS; GENOME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MIDDLE AGED; MOUSE; NONHUMAN; PATIENT DERIVED XENOGRAFT; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC DATABASE; HEAD AND NECK TUMOR; METABOLISM; PROCEDURES; SQUAMOUS CELL CARCINOMA;

TUMOR PROTEIN;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CLUSTER ANALYSIS; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTEOMICS;

EID: 84962226262     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0354     Document Type: Article

References (40)

1. Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, et al. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res 2014;12:571-82.
2. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
3. Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther 2012;13:935-45.
4. Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855: 223-34.
5. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013;73:5315-9.
6. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 2014;344:1-12.
7. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
8. Chen J, Milo GE, Shuler CF, Schuller DE. Xenograft growth and histodif-ferentiation of squamous cell carcinomas of the pharynx and larynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:197-202.
9. Hennessey PT, Ochs MF, Mydlarz WW, Hsueh W, Cope L, Yu W, et al. Promoter methylationinhead and neck squamous cell carcinomacell lines is significantly different than methylation in primary tumors and xeno-grafts. PLoS One 2011;6:e20584.
10. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013;19:855-64.
11. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-8.
12. Seshadri M, Merzianu M, Tang H, Rigual NR, Sullivan M, Loree TR, et al. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther 2009;8: 2275-83.
13. Stein AP, Saha S, Liu CZ, Hartig GK, Lambert PF, Kimple RJ. Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. PLoS One 2014;9:e100995.
14. Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, et al. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. J Neurochem 2015;133:730-8.
15. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013;4:1116-30.
16. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013;73:4885-97.
17. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010;16:2852-60.
18. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysisofprimary leukemia specimens andhematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21.
19. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-94.
20. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, et al. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioin-formatics 2015;31:912-8.
21. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 2014;5:3887.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
23. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Sche-partz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84: 1424-31.
24. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-73.
25. Lawrence MS, Sougnez C, Lichtenstein L, Cibulskisl K, Lander E, Gabriel SB, et al. Comprehensive genomic characterization of head and neck squa-mous cell carcinomas. Nature 2015;517:576-82.
26. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. Themutational landscapeofhead and neck squamous cellcarcinoma. Science 2011;333:1157-60.
27. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761-9.
28. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 2015;17:256-64.
29. Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, et al. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med 2013;11:198.
30. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008;14:6456-68.
31. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
32. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK Jr, et al. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 2004;64:1712-21.
33. Sanz L, Cuesta AM, Salas C, Corbacho C, Bellas C, Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest 2009;89: 91-7.
34. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 1992;89: 5645-9.
35. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature Protoc 2009;4: 1670-80.
36. Mueller BM, Reisfeld RA. Potential of the scid mouse as a host for human tumors. Cancer Metastasis Rev 1991;10:193-200.
37. Eckhardt SG. Challenges to Pdtx models in drug development. Ann Oncol 2013;24:15.
38. Kopetz S, Lemos R, Powis G. The promiseofpatient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 2012;18:5160-2.
39. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101:4966-71.
40. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods 2013;10:1046-7.